Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Authors:
- 21 June 2025
- journal article
- research article
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 13 (9) , 777-789
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Tirzepatide for Weight Reduction in Chinese Adults With ObesityJAMA, 2024
- Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?Metabolism, 2024
- Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analogMolecular Metabolism, 2023
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialJournal of Hepatology, 2022
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialThe Lancet, 2021
- Epidemiology and determinants of obesity in ChinaThe Lancet Diabetes & Endocrinology, 2021
- The epidemiology of obesityMetabolism, 2019
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in MenArchives of internal medicine (1960), 2005